Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05455281 · ClinicalTrials.gov registry record
Performance of CHLOE Algorithm on the Prediction of Blastocyst Formation
A clinical trial, sponsored by Fairtility.
- Completed
- Registry status
- 55
- Enrollment target
NCT05455281: Completed study, sponsored by Fairtility.
NCT05455281 is a clinical trial that has completed, run by Fairtility. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05455281 has completed, sponsored by Fairtility.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
This is an observational, prospective, single-arm, multi-center, clinical study to evaluate the performance of CHLOE, an Artificial Intelligence (AI)-based software application, as adjunct information to support identifying embryos on Day 3 that are most likely to form blastocysts.
Primary Outcome
The prediction of blastocyst outcome using CHLOE algorithm, and the actual blastocyst outcome for a subset of good/fair embryos will be measured using odds ratio.
Interventions
- DEVICE CHLOE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2023-07-27 |
What the finished NCT05455281 record still lists
NCT05455281 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CHLOE is the first listed.
NCT05455281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05455281 about?
NCT05455281 is a clinical study titled "Performance of CHLOE Algorithm on the Prediction of Blastocyst Formation". This is an observational, prospective, single-arm, multi-center, clinical study to evaluate the performance of CHLOE, an Artificial Intelligence (AI)-based software application, as adjunct information to support identifying embryos on Day 3 that are most likely to form blastocysts.
What is the current status of trial NCT05455281?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2022-07-27. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT05455281?
The interventions under investigation include: CHLOE (DEVICE).
Who is sponsoring clinical trial NCT05455281?
This trial is sponsored by Fairtility, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI